Completing the experience creates a greater understanding of the characteristics of treatment-resistant cells and importance of testing for minimal residual disease in multiple myeloma (MM) patients to improve outcomes.
Completing the experience creates a greater understanding of the characteristics of treatment-resistant cells and importance of testing for minimal residual disease in multiple myeloma (MM) patients to improve outcomes.